American Cancer Society Seeks $11 Billion to Pursue an 80% Gardasil Vaccination Rate Among U.S. Children

The American Cancer Society (ACS) has set an aggressive goal to achieve an 80 percent uptake rate among American children with two doses human papillomavirus (HPV) vaccine by 2026. To gain that coverage, 14 million more preteen children would need to complete the two-dose series, for a total of 57.62 million doses above and beyond the number of vaccinations given to date. HPV vaccine is one of the most expensive vaccines on the CDC recommended childhood vaccine schedule, costing a pricey $168 to $204 per dose, with Merck being the sole producer of HPV vaccine (Gardasil) in the U.S. Although U.S. health officials have continued to deny a causal connection, Japanese researchers have pointed out that the temporal association with post-Gardasil clinical symptoms such as “chronic regional pain syndrome, orthostatic intolerance, and/or cognitive dysfunction” suggests a causal relationship with the vaccine. Other health issues associated with HPV vaccination include nervous and immune system disorders such as postural orthostatic tachycardia syndrome (POTS), chronic fatigue syndrome, blood clots, acute respiratory failure and cardiac arrest. Also widely reported are menstrual abnormalities and premature ovarian failure. Using the MedAlerts search engine, as of April 30, 2018, the federal Vaccine Adverse Events Reporting System (VAERS) contained more than 58,992 reports of HPV vaccine reactions, hospitalizations, injuries and deaths including 430 related deaths, 794 hospitalizations, and 2,773 disabling conditions. Over 45 percent of the reported serious adverse events occurred in children and teens 12-17 years of age.

New Gardasil Vaccine Guidelines From American Cancer Society Censors All Risks to Vaccine

The American Cancer Society issued a press release recently stating that they were agreeing with the U.S. Center for Disease Control's (CDC) recommendation to now start vaccinating boys as well as girls with the Gardasil vaccine, and that Gardasil vaccines can begin as young as age 9. Noticeably absent from the press release was any warnings on Gardasil risks and side effects, or any mention of how other countries around the world are now investigating the vaccine due to the amount of injuries being reported. Japan and other nations have actually withdrawn their recommendation of the HPV vaccine. Because the manufacturers of vaccines are not immune from liabilities due the harm their vaccines cause in these countries, in contrast to the United States where one cannot sue a vaccine manufacturer, many are taking legal actions against HPV manufacturers. You will read none of this in U.S. mainstream media.

Boycott of Komen Foundation and American Cancer Society: They Don’t Want Cures, Just Your Money

Does wearing constrictive bras for long periods of time daily contribute to breast cancer? It does, according to at least 5 research studies and numerous healthcare providers, including oncologists and MD’s. Even some lingerie manufacturers have developed new bra designs hoping to minimize lymphatic constriction and thereby help prevent breast cancer, citing the bra-cancer link for their patents. But bras are not related to cancer according to the American Cancer Society and the Susan G. Komen Foundation, fund raising giants of the cancer detection and treatment world. They consider the link absurd and unworthy of serious consideration, and unquestionably assume that research showing a link must have some other explanation besides bras. Could shrugging off the bra-cancer link be killing hundreds of thousands of women and wasting billions of dollars in unnecessary detection and treatment?

American Cancer Society: The World’s Wealthiest “Nonprofit” Institution is Losing the War on Cancer

The American Cancer Society is fixated on damage control— diagnosis and treatment— and basic molecular biology, with indifference or even hostility to cancer prevention. This myopic mindset is compounded by interlocking conflicts of interest with the cancer drug, mammography, and other industries. The "nonprofit" status of the Society is in sharp conflict with its high overhead and expenses, excessive reserves of assets and contributions to political parties. All attempts to reform the Society over the past two decades have failed; a national economic boycott of the Society is long overdue.